ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behçet’s Syndrome"

  • Abstract Number: 0408 • ACR Convergence 2020

    Epidemiology and Treatment of Behçet’s Disease Insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Nevin Hammam1, Jinoos Yazdany2 and Gabriela Schmajuk3, 1UCSF, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3University of California, San Francisco, Atherton, CA

    Background/Purpose: Behçet’s disease (BD), a rare multisystem vasculitis, is prevalent among Middle Eastern populations but remains rare in North America. Data for patients with BD…
  • Abstract Number: 0425 • ACR Convergence 2020

    MAGIC Syndrome in a Cohort of Patients with Relapsing Polychondritis

    Yiming Luo1, Emily Rose2, Keith Sikora3, Kaitlin Quinn4, Kristina Wells5, Emily Rominger5, Wendy Goodspeed6, Peter C. Grayson7 and Marcela Ferrada6, 1Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 2Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethsda, 3Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, 5Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 6Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 7Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is an extremely rare condition that encompasses symptoms of relapsing polychondritis (RP) and Behcet’s disease…
  • Abstract Number: 0459 • ACR Convergence 2020

    Autologous Hematopoietic Stem Cell Transplantation for Behçet’s Disease: A Retrospective Survey of Patients Treated in Europe, on the Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Bone Marrow Transplantation

    Mathieu Puyade1, Patel Amit2, Yeong Jer Lim3, Norbert Blank4, Manuela Badoglio5, Francesca Gualandi6, David D Ma7, Raffaella Greco8, Natalia Maximova9, Tobias Alexander10 and John A Snowden11, 1Service de Médecine Interne et Maladies Infectieuses ,CIC-1402 Centre Hospitalier Universitaire de Poitiers, Poitiers, France, 2The Christie NHS Foundation Trust, Manchester, United Kingdom, 3University of Liverpool, Liverpool, United Kingdom, 4Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, 5EBMT ADWP Office, Paris, France, 6U.O. EMATOLOGIA Centro Trapianti Midollo - OSPEDALE POLICLINICO SAN MARTINO, GENOVA, Italy, 7Department of Haematology and BM Transplantation, St Vincent’s Hospital Sydney and St Vincent’s Clinical School, Faculty of Medicine, Sidney, New South Wales, Australia, 8Ematologia Trapianto Midollo San Raffaele, Milano, Italy, 9Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Trieste, Italy, 10Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, 11Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

    Background/Purpose: Behçet’s Disease (BD) is a rare autoimmune disease mostly presenting with recurrent oral and genital aphtosis, ulcers, and uveitis. Rare patients are refractory to…
  • Abstract Number: 0511 • ACR Convergence 2020

    ERAP1-mediated Immunogenicity and Immune-phenotypes in HLA-B51+ Behçet’s Disease Point to Pathogenic CD8 T Cell Effector Responses

    Ann Cavers1, Yesim Ozguler2, Olivier Manches3, Arshed Al-Obeidi1, Hua Zhong1, Beatrix Ueberheide1, Gülen Hatemi4, Matthias Kugler1 and Johannes Nowatzky5, 1NYU School of Medicine, New York, 2Istanbul University Cerrahpaşa Medical School, Istanbul, Turkey, 3Inserm, U 1209, Grenoble, France, 4Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 5New York University School of Medicine, New York, NY

    Background/Purpose: HLA-B51 is a definite risk factor for Behçet’s disease (BD). A coding variant of ERAP1, Hap10 – with low peptide-trimming activity – vastly potentiates…
  • Abstract Number: 0512 • ACR Convergence 2020

    Efficacy of Apremilast for the Treatment of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and Arthritis

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

    Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful and recurrent oral ulcers (OU) and other manifestations, such as skin lesions and…
  • Abstract Number: 1429 • ACR Convergence 2020

    An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US

    Kathryn Starzyk1, Kimberly Milberg1, Ashish Deshpande1 and Gary Curhan1, 1OM1, Inc, Boston, MA

    Background/Purpose: The mainstay of treatment for vasculitis has been corticosteroids and other cytotoxic and immunosuppressive medications (e.g., cyclophosphamide, methotrexate) to promptly achieve and maintain remission.…
  • Abstract Number: 1638 • ACR Convergence 2020

    Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients

    David Martinez-Lopez1, Lara Sanchez-Bilbao2, Carmen Alvarez-Reguera2, Alba Herrero Morant2, Inigo Gonzalez-Mazon3, José Luis Martín-Varillas4, Guillermo Suarez-Amorin2, Patricia Setien-Preciados2, Cristina Mata-Arnaiz5, Miguel Ángel González-Gay6 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Sierrallana, Torrelavega, Spain, 5Hospital de Laredo, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Behçet’s disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and…
  • Abstract Number: 0092 • ACR Convergence 2020

    Diagnosis of Behçet’s Disease: Comparison of Two Sets of Classification Criteria. Application in 111 Patients of a Well-defined Population

    David Martinez-Lopez1, Alba Herrero Morant2, Carmen Alvarez-Reguera2, Lara Sanchez-Bilbao2, Inigo Gonzalez-Mazon3, José Luis Martín-Varillas4, Guillermo Suarez-Amorin2, Patricia Setien-Preciados2, Cristina Mata-Arnaiz5, Miguel Ángel González-Gay6 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Bezana, Spain, 4Hospital Sierrallana, Torrelavega, Spain, 5Hospital de Laredo, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Behçet’s disease (BD) is a systemic, chronic, relapsing vasculitis with no pathognomonic diagnostic test. The most widely used classification criteria are those of the…
  • Abstract Number: 0405 • ACR Convergence 2020

    Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

    Background/Purpose: Recurrent, painful oral ulcers (OU) are common symptoms of Behçet’s syndrome that can impact daily activities and impair quality of life (QoL) (Kokturk A.…
  • Abstract Number: 0406 • ACR Convergence 2020

    Infliximab in Refractory Uveitis Due to Behçet’s Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo2, Vanesa Calvo-Río3, Emma Beltran-Catalan4, Alfredo Adan5, Marisa Hernandez Garfella6, Elia Valls-Pascual7, Agustín Sellas-Fernández8, N Ortego9, Alejandro Fonollosa10, Olga Maiz Alonso11, Ignacio Torre12, Cruz Fernández-Espartero13, Vega Jovani14, Diana Peiteado15, David Díaz Valle16, Susana Romero-Yuste17, Elena Aurrecoechea1, Miriam García-Arias18, Miguel Ángel Caracuel19, Santos Insúa20, Senén González-Suárez21, Amalia Sánchez Andrade22, Luis Francisco Linares23, Alfredo J García González24, Raquel Almodovar25, Carmen Carrasco Cubero26, María Alcalde Villar27, C Fernandez-Carballido28, Fred A Pages29, Eva Peña Sainz-Pardo24, Rosalia Demetrio-Pablo3, Santos Castañeda30, Miguel Ángel González-Gay31, José Luis Hernández3 and Ricardo Blanco3, 1Hospital Sierrallana, Torrelavega, Spain, 2Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Del Mar University Hospital, Barcelona, 5Hospital Clinic, Barcelona, Catalonia, Spain, 6H. Valencia, Valencia, Spain, 7H. Doctor Peset, Valencia, Spain, 8H. Vall d'Hebron, Barcelona, Spain, 9H. San Cecilio, Granada, Spain, 10H. de Cruces, Bilbao, Spain, 11Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, 12Hospital Basurto, Bilbao, Spain, 13H. Mostoles, Madrid, Spain, 14H. Alicante, Alicante, Spain, 15Hospital La Paz - IdiPAZ, Madrid, Spain, 16H. Clínico San Carlos, Madrid, Spain, 17H Pontevedra, Coruna, Spain, 18H. La Princesa, Madrid, 19H.U. Reina Sofía, Córdoba, Spain, 20H. Santiago de Compostela, Santiago de Compostela, Spain, 21H. Cabueñes, Gijón, Spain, 22H. Lucus Augusti, Lugo, Spain, 23Hospital de la Arrixaca, Murcia, 24H. 12 de Octubre, Madrid, Spain, 25Fundación Alcorcón University Hospital, Madrid, 26H. Mérida, Mérida, Spain, 27H. Severo Ochoa, Madrid, Spain, 28H San Juan, Alicante, Spain, 29H. Palencia, Palencia, Spain, 30Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 31Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Biologic therapy has improved prognosis of Behçet Disease (BD) uveitis. Although infliximab (IFX) is approved in Japan, most data in Caucasian patients comes from…
  • Abstract Number: 0407 • ACR Convergence 2020

    Achievement of Early and Sustained Complete Response of Oral Ulcers with Apremilast Compared with Placebo in Patients with Active Behçet’s Syndrome

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

    Background/Purpose: Painful and recurring oral ulcers (OU) are a common manifestation of Behçet’s syndrome that can interfere with eating and have a negative impact on…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology